That is a tough one I immediately thought of Sylvan Esso I thought they were Irish they are from America. Then I thought of Karen O. Rap and the Irish.. not exactly a natural fit- Karen O'Keefe is an Irish descendant.<---- Karen O is a vocalist, songwriter, artist and the iconicfrontwomanof the Yeah Yeah Yeahs.<------- This is a great song-
Look at this article every single damn security stock is named except SENTINEL 1!!!!!!!! Security stocks expected to gain more strength as network breaches continue Sep. 17, 2022 12:00 PM ETFortinet, Inc. (FTNT), ZS, PANW, CRWDCYBR, UBER On Friday, Uber (UBER) said that a recent security breach didn't involve a leak of any sensitive data of its customers or drivers. Still, the fact that a company of Uber's (UBER) size can get hacked serves notice that network security is a matter can't be ignored by any organization. It's incidents like this that continue to provide opportunities for companies in the cybersecurity sector. And the market is such that MKM Partners analyst Catharine Trebnick on Friday initiated covered of five big-name security companies with buy ratings: Fortinet (NASDAQ:FTNT), Zscaler (NASDAQ:ZS), Palo Alto Networks (NASDAQ:PANW), CyberArk (CYBR) and CrowdStrike Holdings (NASDAQ:CRWD). In addition to putting a buy rating on Fortinet (FTNT), Trebnick set a price target of $70 a share on the company's stock. Trebnick said that in the current business environment, Fortinet (FTNT) has several competitive advantages that put it in a strong position in the security market. Among those are a single "pane of glass" that allows for monitoring of network traffic across multiple devices, a broad portfolio of products and what Trebnick said was a path for Fortinet (FTNT) to reach $10B in billings by 2025. Trebnick said that Zscaler (ZS) presents "an attractive long-term growth opportunity" as it provides "seamless protection regardless of location, geography, office, home and/or public WiFI [networks]." Trebnick set a price target of $225 a share on Zscaler's (ZS) stock, saying that the company's "competitive advantages are sustainable" and will enable it grow revenue at 30% year-over-year for the foreseeable future. For CyberArk (CYBR), Trebnick set a $190-a-share price target on the company's stock, and said that its transition to a subscription business model "came in ahead of plan," and that its annual recurring revenue growth is coming in higher than its overall revenue growth rate. Trebnick added that with about 8,000 customers now, CyberArk (CYBR) is on a path to grow by 20,000 customers in 2025. For CrowdStrike (CRWD), Trebnick said the company has "one of the most comprehensive cloud-native platforms" in the cybersecurity industry. Trebnick said this allows CrowdStrike (CRWD) to move beyond endpoint security and into areas such as cloud security and identity protection. In addition to setting a buy rating on CrowdStrike (CRWD), Trebnick put a price target of $240 a share on the company's stock. With regards to Palo Alto Networks (PANW), Trebnick said Chief Executive Nikesh Arora "has been instrumental in transitioning Palo Alto Networks to a SaaS [software-as-a-service] based model focused on next-generation cybersecurity." Trebnick said with its annual recurring revenue from next-generation security offerings rising to $1.9B in its most-recent quarter, the company should be able to expand its market share and cloud-based services gain more popularity with businesses. Trebnick also set a $250-a-share price target on Palo Alto Networks (PANW) stock. On Thursday, Palo Alto Networks (PANW) shares ended the day in the red as the company enacted a 3-for-1 stock split.
Late Night Tales: Snow Patrol- This is as close as you will get Van. Compilation albumby Snow Patrol Released 21 September 2009 Recorded Jacobs Studios,Farnham Mayfair Studios,London Genre Alternative rock,house,electronic,indie rock,rap Length 67:59 Label Night Time Stories Producer Gary Lightbody,Tom Simpson Compiler Gary Lightbody, Tom Simpson Snow Patrolchronology The Trip: Created by Snow Patrol (2004) Late Night Tales: Snow Patrol (2009) Up to Now (2009) Late Night Taleschronology Late Night Tales: Matt Helders (2008) Late Night Tales: Snow Patrol (2009) Late Night Tales: The Cinematic Orchestra (2010) Late Night Tales: Snow Patrolis a mix album compiled byalternative rockbandSnow Patrol's membersGary LightbodyandTom Simpsonand released throughNight Time Stories[1]in September and October 2009. The album is the 22nd in theLate Night Talesseries.[2]It was recorded at Jacobs Studios inFarnham& Mayfair Studios inLondon,[3]and was produced by compilers Lightbody and Simpson.[1]
New iPhones have Qualcomm satellite modem, Reuters reports 16:56 AAPL, QCOM Apple's (AAPL) iPhone 14 models contain a Qualcomm (QCOM) chip that can talk to satellites, but have additional custom-designed Apple components used in the phone's biggest new feature, according to an analysis of the phone by iFixit and an Apple statement, Reuters' Stephen Nellis reports. Apple released its iPhone 14 lineup on Friday. One of the major new features is the ability to connect to satellites to send emergency messages when there is no WiFi or cellular data connection, the author notes.
Volkswagen targets 75B EUR for Porsche IPO valuation, Bloomberg says 16:36 VWAGY, POAHY Volkswagen (VWAGY)
Bluebird receives FDA accelerated approval for SKYSONA for early, active CALD 15:53 BLUE Bluebird Bio announced the U.S. Food and Drug Administration has granted Accelerated Approval of SKYSONA, also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy. The company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. CALD is a rare, progressive, neurodegenerative disease that primarily affects young boys and causes irreversible, devastating neurologic decline, including major functional disabilities such as loss of communication, cortical blindness, requirement for tube feeding, total incontinence, wheelchair dependence, or complete loss of voluntary movement. Nearly half of patients who do not receive treatment die within five years of symptom onset. Prior to the approval of SKYSONA treatment, effective options were limited to allogeneic hematopoietic stem cell transplant, which is associated with the risk of serious potential complications including death, that can increase dramatically in patients without a human leukocyte antigen matched donor. As a condition of the SKYSONA Accelerated Approval, bluebird has agreed to provide confirmatory long-term clinical data to the FDA. bluebird anticipates that this will include data from the ongoing long-term follow-up study, which follows patients treated in clinical trials for 15 years, and from commercially treated patients. Bluebird anticipates that commercial product will be available by the end of 2022 through a limited number of Qualified Treatment Centers in the United States, including Boston Children's Hospital and Children's Hospital of Philadelphia. Bluebird has set the wholesale acquisition cost of SKYSONA in the U.S. at $3.0M. The SKYSONA Biologics License Application was reviewed by the U.S. FDA under Priority Review, and bluebird received a rare pediatric priority review voucher upon approval. SKYSONA was previously granted Orphan Drug designation, Rare Pediatric Disease designation, and Breakthrough Therapy designation.
MON WATCH bluebird bio, Inc. (BLUE) NasdaqGS - NasdaqGS Real Time Price. 6.34-0.75 (-10.58%) At close: September 16 04:00PM EDT